Kushner BH, Meyers PA. How effective is dose-intensive/myeloablative therapy against Ewing's sarcoma/primitive neuroectodermal tumor metastatic to bone or bone marrow? The Memorial Sloan-Kettering experience and a literature review.. J Clin Oncol. 2001; 19 :870-880
Kushner BH, Kramer K, Meyers PA, Wollner N, Cheung NK.. Pilot study of topotecan and high-dose cyclophosphamide for resistant pediatric solid tumors.. Med Pediatr Oncol 2000; 35 :468-74
Wei G, Antonescu CR, de Alava E, Leung D, Huvos AG, Meyers PA, Healey JH, Ladanyi M.. Prognostic impact of INK4A deletion in Ewing sarcoma.. Cancer 2000; 89 :793-9
de Alava E, Antonescu CR, Panizo A, Leung D, Meyers PA, Huvos AG, Pardo-Mindan FJ, Healey JH, Ladanyi M.. Prognostic impact of P53 status in Ewing sarcoma.. Cancer 2000; 89 :783-92
Shamberger RC, Laquaglia MP, Krailo MD, Miser JS, Pritchard DJ, Gebhardt MC, Healey JH, Tarbell NJ, Fryer CJ, Meyers PA, Grier HE.. Ewing sarcoma of the rib: results of an intergroup study with analysis of outcome by timing of resection.. J Thorac Cardiovasc Surg. 2000; 119 :1154-61
Saenz NC, Hass DJ, Meyers P, Wollner N, Gollamudi S, Bains M, LaQuaglia MP.. Pediatric chest wall Ewing's sarcoma.. J Pediatr Surg. 2000; 35 :550-5
Gorlick R, Huvos AG, Heller G, Aledo A, Beardsley GP, Healey JH, Meyers PA.. Expression of HER2/erbB-2 correlates with survival in osteosarcoma. J Clin Oncol 1999; 19 :2781-8
Guo W, Gorlick R, Ladanyi M, Meyers PA, Huvos AG, Bertino JR, Healey JH.. Expression of bone morphogenetic proteins and receptors in sarcomas. Clin Orthop 1999; 365 :175-83
Flombaum CD, Meyers PA.. High-dose leucovorin as sole therapy for methotrexate toxicity.. J Clin Oncol 1999; 17 :1589-94
Guo W, Healey JH, Meyers PA, Ladanyi M, Huvos AG, Bertino JR, Gorlick R.. Mechanisms of methotrexate resistance in osteosarcoma. Clin Cancer Res 1999; 5 :621-7
Kushner BH, Heller G, Cheung NK, Wollner N, Kramer K, Bajorin D, Polyak T, Meyers PA.. High risk of leukemia after short-term dose-intensive chemotherapy in young patients with solid tumors.. J Clin Oncol 1998; 16 :3016-20
Wunder JS, Paulian G, Huvos AG, Heller G, Meyers PA, Healey JH.. The histological response to chemotherapy as a predictor of the oncological outcome of operative treatment of Ewing sarcoma.. J Bone Joint Surg Am. 1998; 80 :1020-33
Meyers PA, Gorlick R, Heller G, Casper E, Lane J, Huvos AG, Healey JH.. Intensification of preoperative chemotherapy for osteogenic sarcoma: results of the Memorial Sloan-Kettering (T12) protocol.. J Clin Oncol 1998; 16 :2452-8
de Alava E, Kawai A, Healey JH, Fligman I, Meyers PA, Huvos AG, Gerald WL, Jhanwar SC, Argani P, Antonescu CR, Pardo-Mindan FJ, Ginsberg J, Womer R, Lawlor ER, Wunder J, Andrulis I, Sorensen PH, Barr FG, Ladanyi M.. EWS-FLI1 fusion transcript structure is an independent determinant of prognosis in Ewing's sarcoma. J Clin Oncol 1998; 16 :1248-55
Kawai A, Huvos AG, Meyers PA, Healey JH.. Osteosarcoma of the pelvis. Oncologic results of 40 patients.. Clin Orthop 1998; 348 :196-207
Imbriaco M, Yeh SD, Yeung H, Zhang JJ, Healey JH, Meyers P, Huvos AG, Larson SM.. Imbriaco M, Yeh SD, Yeung H, Zhang JJ, Healey JH, Meyers P, Huvos AGThallium-201 scintigraphy for the evaluation of tumor response to preoperative chemotherapy in patients with osteosarcoma, Larson SM.. Cancer 1997; 80 :1507-12
Meyers PA, Gorlick R.. Osteosarcoma. Pediatr Clin North Am. 1997; 44 :973-89
Hwang ES, Gerald W, Wollner N, Meyers P, La Quaglia MP.. Leiomyosarcoma in childhood and adolescence.. Ann Surg Oncol 1997; 4 :223-7
O'Reilly R, Link M, Fletcher B, Gebhardt M, Krance R, Meyers P, Neff J, Schwartz C.. NCCN pediatric osteosarcoma practice guidelines. The National Comprehensive Cancer Network.. Oncology 1996; 10 :1799-806
Terek RM, Brien EW, Marcove RC, Meyers PA, Lane JM, Healey JH.. Treatment of femoral Ewing's sarcoma. Cancer 1996; 78 :70-8
Kushner BH, LaQuaglia MP, Wollner N, Meyers PA, Lindsley KL, Ghavimi F, Merchant TE, Boulad F, Cheung NK, Bonilla MA, Crouch G, Kelleher JF Jr, Steinherz PG, Gerald WL.. Desmoplastic small round-cell tumor: prolonged progression-free survival with aggressive multimodality therapy.. J Clin Oncol 1996; 14 :1526-31
Kushner BH, Meyers PA, Gerald WL, Healey JH, La Quaglia MP, Boland P, Wollner N, Casper ES, Aledo A, Heller G, et al.. Very-high-dose short-term chemotherapy for poor-risk peripheral primitive neuroectodermal tumors, including Ewing's sarcoma, in children and young adults. J Clin Oncol 1995; 13 :2796-804
Meyers PA, Heller G, Healey JH, Huvos A, Applewhite A, Sun M, LaQuaglia M.. Osteogenic sarcoma with clinically detectable metastasis at initial presentation.. J Clin Oncol 1993; 11 :449-53
Toguchida J, Yamaguchi T, Dayton SH, Beauchamp RL, Herrera GE, Ishizaki K, Yamamuro T, Meyers PA, Little JB, Sasaki MS, et al.. Prevalence and spectrum of germline mutations of the p53 gene among patients with sarcoma.. N Engl J Med 1992; 326 :1301-8
Meyers PA, Heller G, Healey J, Huvos A, Lane J, Marcove R, Applewhite A, Vlamis V, Rosen G.. Chemotherapy for nonmetastatic osteogenic sarcoma: the Memorial Sloan-Kettering experience. J Clin Oncol 1992; 10 :5-15
Return to Paul A. Meyers, MD Main Page.
